Y337A_human-ACHE

Gene Locus : human-ACHE

Mode of mutation : Site directed mutagenesis

Disease :

Summary : Signal transduction Decrease in catalytic and apparent bimolecular constant Shafferman_1992_EMBO.J_11_3561 Barak_1994_J.Biol.Chem_269_6296 Ordentlich_1995_J.Biol.Chem_270_2082 || Substrate inhibition absence of substrate inhibition Shafferman_1992_EMBO.J_11_3561 Barak_1994_J.Biol.Chem_269_6296 Ordentlich_1995_J.Biol.Chem_270_2082 || Oxime interaction Cochran_2011_J.Biol.Chem_286_29718 || Acyl specificity replacement of aromatic active center residues in human-ACHE by the corresponding residues in human-BCHE Kaplan_2001_Biochemistry_40_7433 || oxime interaction reactivation of tabun-inhibited human AChE. Unable to facilitate HI-6-mediated reactivation of tabun-hAChE Artursson_2009_Toxicology_265_108

AAA Change :

Allelic Variant :

Risk Factor :

Inhibitor :

Structure :

Disease by interaction :

Interact Gene Locus :

Xenobiotic sensitivity :

Modification : Signal transduction || Substrate inhibition || Oxime interaction || Acyl specificity

Torpedo_number : 330

Kinetic Parameter : Edrophonium_Y337A_human-ACHE, Paranitrophenylacetate_Y337A_human-ACHE, S-N-Propylthioacetate_Y337A_human-ACHE, 3,3-dimethylbutylthioacetate_Y337A_human-ACHE, Acetylthiocholine_Y337A_human-ACHE, Hexamethonium_Y337A_human-ACHE, BW284C51_Y337A_human-ACHE, Propidium_Y337A_human-ACHE, Decamethonium_Y337A_human-ACHE, Tacrine_Y337A_human-ACHE, HuperzineA_Y337A_human-ACHE, Butyrylthiocholine_Y337A_human-ACHE

News : No news

Comment : p.Y337A Tyr337Ala (p.Y368A Tyr368Ala in primary sequence with 31 amino-acids signal peptide)\;Decrease in catalytic and apparent bimolecular constant Substrate inhibition\;absence of substrate inhibition\; Acyl specificity\;replacement of aromatic active center residues in human-ACHE by the corresponding residues in human-BCHE\; Oxime interaction\; reactivation of tabun-inhibited human AChE. Unable to facilitate HI-6-mediated reactivation of tabun-hAChE\; The phosphoramidated-hAChE choline-binding site mutant Y337A showed three-times enhanced reactivation capacity with non-triazole imidazole containing aldoximes than with 2PAM